Xingwang Xie
- Hepatology top 5%
- Hepatitis C virus research 6
- Cancer Research top 10%
- Immunology top 10%
- Immune Cell Function and Interaction 7
- Immunotherapy and Immune Responses 4
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers 7
- Epidemiology top 10%
- Hepatitis B Virus Studies 8
- Liver Disease Diagnosis and Treatment 5
-
- RNA modifications and cancer 6
- Ubiquitin and proteasome pathways 4
- Cited by
- HepatologyCancer ResearchImmunology
- Journals
- Scientific Reports (3 papers)Journal of Experimental & Clinical Cancer Research (3 papers)PLoS ONE (3 papers)
- Partner nations
- China
In The Last Decade
Xingwang Xie
40 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 99
- Hepatology 211
- Cancer Research 253
- Immunology 280
- Oncology 267
- Epidemiology 279
Countries citing papers authored by Xingwang Xie
This map shows the geographic impact of Xingwang Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xingwang Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xingwang Xie more than expected).
Fields of papers citing papers by Xingwang Xie
This network shows the impact of papers produced by Xingwang Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xingwang Xie. The network helps show where Xingwang Xie may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xingwang Xie, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 6 | |
| 5 | 2022 | 3 | |
| 6 | 2021 | 3 | |
| 7 | 2020 | 2 | |
| 8 | Genome-scale CRISPR activation screening identifies a role of ELAVL2-CDKN1A axis in paclitaxel resistance in esophageal squamous cell carcinoma. | 2019 | 24 |
| 9 | 2019 | 19 | |
| 10 | 2018 | 5 | |
| 11 | 2017 | 18 | |
| 12 | 2016 | 25 | |
| 13 | 2015 | 8 | |
| 14 | 2015 | 10 | |
| 15 | 2015 | 217 | |
| 16 | 2015 | 16 | |
| 17 | 2013 | 7 | |
| 18 | 2013 | 6 | |
| 19 | 2013 | 34 | |
| 20 | [Correlation between interleukin-28B genetic polymorphisms and primary hepatocellular carcinoma]. | 2012 | 5 |
About Xingwang Xie
Xingwang Xie is a scholar working on Hepatology, Immunology and Oncology, having authored 42 papers that have together received 1.1k indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (8 papers), Cancer Immunotherapy and Biomarkers (7 papers), Immune Cell Function and Interaction (7 papers), RNA modifications and cancer (6 papers), Hepatitis C virus research (6 papers), Liver Disease Diagnosis and Treatment (5 papers), Ubiquitin and proteasome pathways (4 papers) and Immunotherapy and Immune Responses (4 papers). The work is most often cited by research in Hepatology (211 citations), Cancer Research (253 citations) and Immunology (280 citations). Xingwang Xie has collaborated with scholars based in China. Frequent co-authors include Hongsong Chen, Lai Wei, Ran Fei, Henghui Zhang, Xueyan Wang, Gaixia He, Jinxue Zhou, Yanhui Chen, Hui Zeng and Yaxian Kong. Their work appears in journals such as Scientific Reports, Journal of Experimental & Clinical Cancer Research, PLoS ONE, BMC Surgery and Clinical & Experimental Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.